Interleukin 1 Receptor Antagonist Anakinra, Intravenous Immunoglobulin, and Corticosteroids in the Management of Critically Ill Adult Patients With Hemophagocytic Lymphohistiocytosis

Journal of Intensive Care Medicine

Volumn 34, Issue 9, 2019, Pages 723-731

  Wohlfarth, Philipp ^a   Agis, Hermine ^a   Gualdoni, Guido A ^a   Weber, Johannes ^a   Staudinger, Thomas ^a   Schellongowski, Peter ^a   Robak, Oliver ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

anakinra; hemophagocytic lymphohistiocytosis; intensive care unit

Indexed keywords

ACICLOVIR; ANAKINRA; ANTIFUNGAL AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; C REACTIVE PROTEIN; CORTICOSTEROID; CREATININE; CYCLOPHOSPHAMIDE; FERRITIN; FIBRINOGEN; GANCICLOVIR; HYPERTENSIVE AGENT; HYPERTENSIVE FACTOR; IMMUNOGLOBULIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LACTATE DEHYDROGENASE; PREDNISONE; RITUXIMAB; TRIACYLGLYCEROL; GLUCOCORTICOID; IMMUNOLOGIC FACTOR;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTISYNTHETASE SYNDROME; ARTICLE; ARTIFICIAL VENTILATION; BONE MARROW BIOPSY; BRAIN DAMAGE; BRAIN HEMORRHAGE; CLINICAL ARTICLE; COHORT ANALYSIS; CRITICALLY ILL PATIENT; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS INFECTION; ERYTHROPHAGOCYTOSIS; EXTRACORPOREAL OXYGENATION; FEMALE; FEVER; GRAFT REJECTION; HEART ARREST; HEMOPHAGOCYTIC SYNDROME; HEPATOMEGALY; HISTOLOGY; HUMAN; HYPOXEMIA; INTENSIVE CARE UNIT; LENGTH OF STAY; LIVER INJURY; LOW DRUG DOSE; LUNG INFILTRATE; LUNG TRANSPLANTATION; MALE; MULTIPLE ORGAN FAILURE; NATURAL KILLER CELL; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; RESPIRATORY FAILURE; RETROSPECTIVE STUDY; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SPLENOMEGALY; SURVIVAL RATE; AUSTRIA; COMPLICATION; CRITICAL ILLNESS; INTENSIVE CARE; MIDDLE AGED; MORTALITY; ORGAN DYSFUNCTION SCORE; PROCEDURES;

ADULT; AUSTRIA; CRITICAL CARE; CRITICAL ILLNESS; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; INTENSIVE CARE UNITS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; ORGAN DYSFUNCTION SCORES; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 85030628690     PISSN: 08850666     EISSN: 15251489     Source Type: Journal    
DOI: 10.1177/0885066617711386     Document Type: Article

References (41)

1. Farquhar JW, Claireaux AE. Familial haemophagocytic reticulosis. Arch Dis Child. 1952;27(136):519–525.
2. Scott RB, Robb-Smith A. Histiocytic medullary reticulosis. Lancet. 1939;234(6047):194–198.
3. Brisse E, Wouters CH, Matthys P. Advances in the pathogenesis of primary and secondary haemophagocytic lymphohistiocytosis: differences and similarities. Br J Haematol. 2016;174(2):203–217.
4. Creput C, Galicier L, Buyse S, Azoulay E. Understanding organ dysfunction in hemophagocytic lymphohistiocytosis. Intensive Care Med. 2008;34(7):1177–1187.
5. Aulagnon F, Lapidus N, Canet E. Acute kidney injury in adults with hemophagocytic lymphohistiocytosis. Am J Kidney Dis. 2015;65(6):851–859.
6. Seguin A, Galicier L, Boutboul D, Lemiale V, Azoulay E. Pulmonary involvement in patients with hemophagocytic lymphohistiocytosis. Chest. 2016;149(5):1294–1301.
7. Valade S, Azoulay E, Galicier L. Coagulation disorders and bleedings in critically ill patients with hemophagocytic lymphohistiocytosis. Medicine. 2015;94(40):e1692.
8. Barba T, Maucort-Boulch D, Iwaz J. Hemophagocytic lymphohistiocytosis in intensive care unit: a 71-case strobe-compliant retrospective study. Medicine. 2015;94(51):e2318.
9. Buyse S, Teixeira L, Galicier L. Critical care management of patients with hemophagocytic lymphohistiocytosis. Intensive Care Med. 2010;36(10):1695–1702.
10. Grange S, Buchonnet G, Besnier E. The use of ferritin to identify critically ill patients with secondary hemophagocytic lymphohistiocytosis. Crit Care Med. 2016 20;44(11):e1045–e1053.
11. Raschke RA, Garcia-Orr R. Hemophagocytic lymphohistiocytosis: a potentially underrecognized association with systemic inflammatory response syndrome, severe sepsis, and septic shock in adults. Chest. 2011;140(4):933–938.
12. Hejblum G, Lambotte O, Galicier L. A web-based delphi study for eliciting helpful criteria in the positive diagnosis of hemophagocytic syndrome in adult patients. PloS One. 2014;9(4):e94024.
13. Rice L, Pacheco J. Adult hemophagocytic lymphohistiocytosis: more data; even more questions. Crit Care Med. 2016;44(11):2119–2121.
14. Simon DW, Aneja R, Carcillo JA, Halstead ES. Plasma exchange, methylprednisolone, IV immune globulin, and now anakinra support continued PICU equipoise in management of hyperferritinemia-associated sepsis/multiple organ dysfunction syndrome/macrophage activation syndrome/secondary hemophagocytic lymphohistiocytosis syndrome. Pediatr Crit Care Med. 2014;15(5):486–488.
15. Henter JI, Samuelsson-Horne A, Arico M. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood. 2002;100(7):2367–2373.
16. Carcillo JA, Simon DW, Podd BS. How we manage hyperferritinemic sepsis-related multiple organ dysfunction syndrome/macrophage activation syndrome/secondary hemophagocytic lymphohistiocytosis histiocytosis. Pediatr Crit Care Med. 2015;16(6):598–600.
17. Sumegi J, Barnes MG, Nestheide SV. Gene expression profiling of peripheral blood mononuclear cells from children with active hemophagocytic lymphohistiocytosis. Blood. 2011;117(15):e151–160.
18. Nigrovic PA, Mannion M, Prince FH. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 2011 2;63(2):545–555.
19. Shakoory B, Carcillo JA, Chatham WW. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial. Crit Care Med. 2016;44(2):275–281.
20. Miettunen PM, Narendran A, Jayanthan A, Behrens EM, Cron RQ. Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. Rheumatology. 2011;50(2):417–419.
21. Rajasekaran S, Kruse K, Kovey K. Therapeutic role of anakinra, an interleukin-1 receptor antagonist, in the management of secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction/macrophage activating syndrome in critically ill children. Pediatr Crit Care Med. 2014;15(5):401–408.
22. Divithotawela C, Garrett P, Westall G, Bhaskar B, Tol M, Chambers DC. Successful treatment of cytomegalovirus associated hemophagocytic lymphohistiocytosis with the interleukin 1 inhibitor—anakinra. Respirol Case Rep. 2016;4(1):4–6.
23. Henter JI, Horne A, Arico M. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124–131.
24. Fardet L, Galicier L, Lambotte O. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014;66(9):2613–2620.
25. Vincent JL, Moreno R, Takala J. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22(7):707–710.
26. Oken MM, Creech RH, Tormey DC. Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol. 1982;5(6):649–655.
27. Hayden A, Park S, Giustini D, Lee AY, Chen LY. Hemophagocytic syndromes (HPSs) including hemophagocytic lymphohistiocytosis (HLH) in adults: a systematic scoping review. Blood Rev. 2016;30(6):411–420.
28. Beutel G, Wiesner O, Eder M. Virus-associated hemophagocytic syndrome as a major contributor to death in patients with 2009 influenza A (H1N1) infection. Crit Care. 2011;15(2):R80.
29. Demirkol D, Yildizdas D, Bayrakci B. Hyperferritinemia in the critically ill child with secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction syndrome/macrophage activation syndrome: what is the treatment? Crit Care. 2012;16(2):R52.
30. Das R, Guan P, Sprague L. Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis. Blood. 2016;127(13):1666–1675.
31. Maschalidi S, Sepulveda FE, Garrigue A, Fischer A, de Saint Basile G. Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice. Blood. 2016;128(1):60–71.
32. Faguer S, Vergez F, Peres M. Tocilizumab added to conventional therapy reverses both the cytokine profile and CD8+Granzyme+ T-cells/NK cells expansion in refractory hemophagocytic lymphohistiocytosis. Hematol Oncol. 2016;34(1):55–57.
33. Teachey DT, Rheingold SR, Maude SL. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood. 2013;121(26):5154–5157.
34. Locatelli F, Allen C, De Benedetti F. A novel targeted approach to the treatment of hemophagocytic lymphohistiocytosis (HLH) with an anti-interferon gamma (IFNγ) monoclonal antibody (mAb), NI-0501: first results from a pilot phase 2 study in children with primary HLH. Blood. 2015;126(23):LBA-3.
35. Sparacino NL, Raschke RA, Curry SC. Outcomes of etoposide based treatment of acquired hemophagocytic lymphohistiocytosis in adult critically ill patients (Abstract). Am J Respir Crit Care Med. 2015;191:A5878–A5878.
36. Walton AH, Muenzer JT, Rasche D. Reactivation of multiple viruses in patients with sepsis. PloS One. 2014;9(2):e98819.
37. Wohlfarth P, Staudinger T, Sperr WR. Prognostic factors, long-term survival, and outcome of cancer patients receiving chemotherapy in the intensive care unit. Ann Hematol. 2014;93(10):1629–1636.
38. Schram AM, Berliner N. How I treat hemophagocytic lymphohistiocytosis in the adult patient. Blood. 2015;125(19):2908–2914.
39. Ramos-Casals M, Brito-Zeron P, Lopez-Guillermo A, Khamashta MA, Bosch X. Adult haemophagocytic syndrome. Lancet. 2014;383(9927):1503–1516.
40. Chellapandian D, Das R, Zelley K. Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens. Br J Haematol. 2013;162(3):376–382.
41. Imashuku S, Kuriyama K, Teramura T. Requirement for etoposide in the treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. J Clin Oncol. 2001;19(10):2665–2673.